Walter E, Weber E
Arzneimittelforschung. 1978;28(10):1778-81.
Adding sulfinpyrazone in a concentration of 500 and 250 microgram/ml to blood of patients with enhanced platelet stickiness a significant decrease (p less than 0.01) of the maximum amplitude and the aggregation velocity could be demonstrated with the spontaneous platelet aggregation test, PAT III, of Breddin, as well as with the collagen and the ristocetin induced aggregation. The lower concentration of 50 microgram/ml of sulfinpyrazone yielded the same results when aggregation was induced with the higher concentrations of 1.5 microgram/ml ristocetin and 5 microgram/ml collagen. Only the maximum aggregation velocity of the PAT III was significantly reduced after addition of 50 microgram sulfinpyrazone/ml blood. With sufficient concentrations of sulfinpyrazone the anti-aggregating action of this substance can very well be demonstrated with the aggregation induced by ristocetin or collagen and the PAT III. The effect is dose dependent.
在血小板黏附性增强的患者血液中加入浓度为500微克/毫升和250微克/毫升的磺吡酮，用布雷丁的自发血小板聚集试验（PAT III）以及胶原和瑞斯托菌素诱导的聚集试验，均可证明最大振幅和聚集速度显著降低（p<0.01）。当用较高浓度的1.5微克/毫升瑞斯托菌素和5微克/毫升胶原诱导聚集时，较低浓度50微克/毫升的磺吡酮产生相同结果。仅在加入50微克磺吡酮/毫升血液后，PAT III的最大聚集速度显著降低。在有足够浓度磺吡酮的情况下，用瑞斯托菌素或胶原诱导的聚集以及PAT III能够很好地证明该物质的抗聚集作用。其作用呈剂量依赖性。
